Xenetic Biosciences, Inc. - XBIO STOCK NEWS

Literacy Texas, a Regions Bank customer and nonprofit organization, is addressing critical literacy challenges in Texas under the leadership of Executive Director Jenny Walker. The organization serves as a support network, collaborating with over 300 nonprofits and government agencies to improve adult and family literacy through resources, training, and advocacy.

Key statistics reveal that 28% of Texas is at level one for reading, and 40% of the population reads at a third-grade level. The organization focuses on developing workforce skills, improving digital literacy, and bridging the technological divide, particularly in rural communities. Low literacy rates nationally cost the U.S. approximately $200 billion in safety and health issues and over $2 trillion in lost productivity annually.

Xenetic Biosciences (NASDAQ:XBIO) has extended its Research Funding Agreement with the University of Virginia (UVA) through 2025 to advance its DNase-based oncology platform. The program targets neutrophil extracellular traps (NETs) in the tumor microenvironment, which promote cancer spread and immunosuppression. Preclinical studies have shown that reducing NETs burden with Xenetic's recombinant human DNase I improves the efficacy of immunotherapy, adoptive cell therapy, and chemotherapy.

The company maintains an option to exclusively license new intellectual property from the research program. UVA will continue investigating DNase I combinations with immunotherapies in primary and metastatic colorectal cancer models. Xenetic is progressing toward its first-in-human study to evaluate DNase combined with immune checkpoint inhibitors or chemotherapy.

Xenetic Biosciences (NASDAQ:XBIO) has entered into a Clinical Trial Services Agreement with Israel-based PeriNess to advance its systemic DNase I oncology program. The collaboration aims to develop XBIO-015, a DNase I candidate, as an adjunctive treatment in combination with chemotherapy and immunotherapy for pancreatic carcinoma, colorectal cancer, and other advanced solid tumors.

Under the agreement, PeriNess will lead regulatory approval and manage potential exploratory studies in Israeli medical centers. The partnership leverages PeriNess' expertise in clinical development of human recombinant DNase. Preclinical data supports DNase I's role in improving therapeutic responses by targeting Neutrophil Extracellular Traps (NETs) in cancer treatment.

Xenetic Biosciences (NASDAQ:XBIO) released a Virtual Investor segment featuring Dr. Reid Bissonnette discussing recent preclinical data presented at the SITC 39th Annual Meeting. The data shows that DNase I significantly improves the effectiveness of anti-CTLA-4 immune checkpoint blockade in preclinical models of microsatellite stable/mismatch repair proficient (MSS/MMRp) colorectal carcinoma. This is particularly significant as MSS/MMRp CRC affects approximately 85% of colorectal cancer patients, a group that has historically shown response to immune checkpoint blockade treatments.

Xenetic Biosciences (NASDAQ:XBIO) presented positive preclinical data showing the potential of co-administering DNase I with CAR T cells in treating melanoma lung metastasis. The study demonstrated that a single injection of DNase I (10 mg/kg) with EGFR-CAR T cells significantly suppressed metastatic tumor burden and extended survival compared to CAR T cell therapy alone. Key findings showed that DNase I increases tumor-infiltrating T and CAR T cells while reducing immunosuppressive effects. The research supports DNase I's potential as an adjunctive treatment to improve CAR T cell therapy responses, particularly in solid tumors where traditional CAR T cell therapy has shown efficacy.

Xenetic Biosciences (NASDAQ:XBIO) reported Q3 2024 financial results, showing a net loss of $0.4 million. R&D expenses decreased by 63.9% to $0.4 million compared to $1.0 million in Q3 2023, primarily due to reduced spending on DNase platform development. The company continues advancing its DNase-based oncology program towards Phase 1 clinical trials for pancreatic carcinoma and other solid tumors. Preliminary preclinical studies combining DNase I with chemotherapy, immuno-therapies, and CAR-T therapy in colorectal cancer models have been completed. The company ended Q3 with $6.8 million in cash.

Xenetic Biosciences (NASDAQ:XBIO) presented positive preclinical data demonstrating that DNase I significantly enhances the effectiveness of anti-CTLA-4 immune checkpoint blockade in colorectal carcinoma models. The study showed that systemic DNase I combined with α-CTLA-4 antibody successfully promoted antitumor immunity and generated immunological memory against microsatellite stable, mismatch repair proficient colorectal carcinoma tumors. Key findings include tumor growth inhibition, complete responses in mice, and enhanced survival rates. The data suggests DNase I impedes neutrophil tumor infiltration while promoting T cell infiltration and activation, potentially addressing unmet needs in cancer treatments where immune checkpoint inhibitors have shown efficacy.

Xenetic Biosciences (NASDAQ:XBIO) announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will take place from November 6-10, 2024, in Houston, Texas and virtually.

The presentation details are as follows:

• Title: DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade in Models of MSS/MMRp CRC
• Abstract Number: 765
• Presenter: Reid Bissonnette, Ph.D., Executive Consultant for Translational Research and Development at Xenetic
• Date and Time: Friday, November 8, 2024, 9:00 a.m.-7:00 p.m. CST
• Location: George R. Brown Convention Center -Level 1 -Exhibit Halls AB

Xenetic Biosciences (NASDAQ:XBIO) has entered into a Materials Transfer Agreement with Tokyo Medical University to advance its systemic DNase program. The agreement involves evaluating the effects of human recombinant DNase I (rhDNase I) in combination with chemotherapy for Ewing sarcoma, an aggressive pediatric cancer.

Professor Takuro Nakamura will lead the research using a proprietary immunocompetent preclinical mouse model. This model reflects the characteristics of human Ewing sarcoma and has shown translational relevance. The study aims to assess DNase's ability to reduce neutrophil extracellular traps (NETs) in the tumor microenvironment and enhance chemotherapy efficacy.

Previous clinical studies at Tel Aviv Medical Center demonstrated that NETs formation in Ewing sarcoma tumors is an independent prognostic factor, with higher NETs levels associated with poor prognosis and treatment response.